Eliem Therapeutics, Inc. Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs
April 05, 2022 at 04:30 pm IST
Share
Eliem Therapeutics, Inc. announced the strengthening of its executive team with the appointment of Susan Franks, MS as Eliem's Senior Vice President and Head of Regulatory Affairs. Ms. Franks brings with her over 30
years of global regulatory affairs and project management experience working at multiple pharmaceutical companies with an emphasis on pain and CNS drug development. Ms. Franks most recently served as the Senior Vice President and Head of Regulatory Affairs at Braeburn Inc., where she was responsible for managing the regulatory team with a focus on its opioid use disorder (OUD) and pain pipeline. Previously, Ms. Franks was Vice President - Global Regulatory Affairs at Teva Pharmaceuticals where she led a 115 person global regulatory organization for Teva's Specialty portfolio of over 40 drug projects in global markets across multiple therapeutic areas including Pain and CNS movement disorders. Prior to Teva Pharmaceuticals, Ms. Franks held positions of increasing responsibility in global regulatory affairs at Cephalon, Premier Research Group, and Wyeth Pharmaceuticals. Over the course of her career, Ms. Franks led the successful registration of Exalgo® (hydromorphone extended release) and Vantrela® ER (hydrocodone), the tentative approval for Brixadi (buprenorphine extended-release) as well as leading several successful FDA Advisory Committees. Ms. Franks holds a BS in Chemistry from Clarkson University and an MS in Chemistry from Lehigh University.
Eliem Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. Its clinical-stage program, ETX-155, is an investigational, oral, neuroactive steroid NCE that is designed to act as a positive allosteric modulator (PAM) of the GABAA receptor (GABAAR). The GABAA PAM neuroactive steroid class has been clinically validated in depression and epilepsy, with Sage Therapeutics receiving approval from the United States. ETX-155 for use in multiple disorders of high unmet need, including major depressive disorder (MDD) and focal onset seizures (FOS). It has designed several lead series based on novel chemistry and selected a lead clinical candidate, ETX-123. The ETX-123 molecule displays potent activation of Kv7.2/3 in vitro with an approximately 0.7 nM EC50.